As of 2025-06-13, the Intrinsic Value of Knight Therapeutics Inc (GUD.TO) is 2.43 CAD. This GUD.TO valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 6.04 CAD, the upside of Knight Therapeutics Inc is -59.70%.
The range of the Intrinsic Value is 1.38 - 23.78 CAD
Based on its market price of 6.04 CAD and our intrinsic valuation, Knight Therapeutics Inc (GUD.TO) is overvalued by 59.70%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | 1.38 - 23.78 | 2.43 | -59.7% |
| DCF (Growth 10y) | 8.33 - 172.53 | 16.08 | 166.3% |
| DCF (EBITDA 5y) | 9.88 - 13.77 | 11.75 | 94.6% |
| DCF (EBITDA 10y) | 13.38 - 20.87 | 16.80 | 178.1% |
| Fair Value | 0.56 - 0.56 | 0.56 | -90.81% |
| P/E | 0.61 - 2.03 | 0.90 | -85.1% |
| EV/EBITDA | 5.04 - 11.19 | 7.04 | 16.6% |
| EPV | 3.06 - 4.51 | 3.79 | -37.3% |
| DDM - Stable | 1.62 - 105.89 | 53.76 | 790.0% |
| DDM - Multi | 6.12 - 318.22 | 12.14 | 101.1% |
| Market Cap (mil) | 601.77 |
| Beta | 0.40 |
| Outstanding shares (mil) | 99.63 |
| Enterprise Value (mil) | 543.53 |
| Market risk premium | 5.10% |
| Cost of Equity | 6.45% |
| Cost of Debt | 15.01% |
| WACC | 6.80% |